Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRON vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: CRON 4 – 2 AYTU Matrix Metrics: CRON 7 – 3 AYTU

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRON carries a Unified Composite Score of 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Technical & Structure Timing Caution: CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.6); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRON vs AYTU
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.26
-3.48% 1D
Market Cap $1.2B
TTM Revenue $206M
Forward P/E 13.3x
Beta / 30D Vol 0.35β · 40% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 46.0 Fund 51.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.6 · SMA20: $3.41 · SMA50: $3.32
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (CRON 4 – 2 AYTU)

Columns: Metric · CRON · AYTU
1. Valuation Multiples AYTU
Forward P/E 13.3x 9.2x
Trailing P/E 21.3x 9.2x
PEG Ratio N/M N/M
EV / Revenue 4.1x 0.3x
2. Growth & Scale CRON
Revenue Growth (YoY) +74.6% +6.4%
Earnings Growth (YoY) -44.7% +0.0%
TTM Revenue (USD) $206M $58M
Market Cap $1.2B $19.6M
3. Profitability & Quality CRON
Gross Margin 46.3% 64.0%
Operating Margin 6.1% -14.4%
Net Profit Margin 28.0% -24.8%
Return on Equity (ROE) 6.1% -52.5%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) $65M -$1.4M
Cash Flow Margin 31.6% -2.4%
Net Cash / Leverage $410M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 45.9% (20th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 40.2% of Rev ($83M) 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRON (7) vs AYTU (3)
Institutional Metric CRON AYTU Criterion Row Edge
Market Capitalization
Scale
$1.2B $19.6M Larger Scale CRON
Trailing P/E Ratio
Valuation
21.3x 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
13.3x 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+74.6% +6.4% Higher Growth CRON
Operating Margin (TTM)
Profitability
6.1% -14.4% Higher Margin CRON
Net Profit Margin
Profitability
28.0% -24.8% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
6.1% -52.5% Higher ROE CRON
52-Week Range Position
Momentum
60% ($2–$4) 5% ($2–$3) Stronger Trend CRON
Beta / 30D Volatility
Risk Regime
0.35β · 40% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
53.9 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite CRON
Trailing 12M Revenue (USD)
Operating Scale
$206M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.3% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.1x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$65M ($410M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +12.9 pp
CRON: +1.63% · AYTU: -11.27%
3M Horizon CRON +24.94 pp
CRON: +1.63% · AYTU: -23.31%
6M Horizon CRON +38.33 pp
CRON: +24.52% · AYTU: -13.81%
1Y Horizon CRON +43.69 pp
CRON: +31.55% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRON Revenue AYTU Revenue CRON Op. Margin AYTU Op. Margin Margin Leader
FY2019 $20M $10M -645.5% -230.1% AYTU
FY2020 $50M $30M -469.6% -76.5% AYTU
FY2021 $60M $70M -452.2% -89.7% AYTU
FY2022 $90M $100M -128.4% -113.7% AYTU
FY2023 $90M $110M -97.2% -15.9% AYTU
FY2024 $120M $70M -65.1% -2.4% AYTU
FY2025 $150M $70M -11.9% -11.8% AYTU
FY2026 N/A $60M N/A -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRON CONSOLIDATION
57d in phase · OBV NEUTRAL
Current IV 45.9%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ CRON vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRON carries a Unified Composite Score of 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Technical & Structure Timing Caution: CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.6); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRON leads the Growth & Scale pillar: CRON posts +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CRON cumulative revenue shifted +650.0% while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, CRON deploys 40.2% of Rev ($83M) (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. CRON trades at 13.3x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (31.6% FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRON (6.1% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CRON carries 45.9% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 40% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.